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A B S T R A C T
Sustained immune activation during chronic HIV infection is considered to augment co-morbidity and
mortality. Eﬀective combination antiretroviral therapy (cART) has shown to dampen immune activation
especially during the ﬁrst year cART, but the eﬀects of long-term cART in patients without major comorbidities
remains under-investigated.
We performed a comprehensive analysis including cellular, intracellular and plasma biomarkers to study the
eﬀect of cART on immune parameters in 5 groups of 10 HIV patients. All patients were without major co-
morbidities and grouped based on cART duration (0, 1, 3, 5, and 10 years). We included 10 matched healthy
controls for comparison. Our data show that after the ﬁrst year of cART, no additional eﬀect on the level of
inﬂammatory markers is observed in HIV infected patients without major co morbidities. Residual immune
activation status in well-treated HIV-infection is similar to levels observed in healthy controls.
1. Introduction
With the introduction of combination anti-retroviral therapy
(cART), HIV-related mortality and morbidity has decreased dramati-
cally. As a result, studies investigating AIDS-related complications are
substituted with studies focusing on long-term health consequences of
HIV infection in patients with cART induced viral suppression
(Paiardini and Müller-Trutwin, 2013; Funderburg, 2014). These stu-
dies draw the picture that successful therapy does not completely
reverse/normalize the inﬂammatory status induced by HIV infection
since sustained activation of the immune system is observed which in
turn leads to non-AIDS-related morbidity such as cardiovascular
disease and non-AIDS related cancers (Lederman et al., 2011; French
et al., 2009; Abraham et al., 2015; Funderburg et al., 2012; Deeken
et al., 2012).
Studies comparing immune parameters in HIV patients and healthy
individuals have shown enhanced levels of the plasma cytokines IL-6
(Armah et al., 2012; Neuhaus et al., 2010; Somsouk et al., 2015; Borges
et al., 2015) and sCD14 (Abraham et al., 2015; Somsouk et al., 2015;
Hattab et al., 2015; Wada et al., 2015), increased inﬂammatory proﬁles
of monocytes (Funderburg et al., 2012; McCausland et al., 2015;
Hearps et al., 2012a) and enhanced frequencies of activated CD8+ T
cells as determined by CD38 and HLA-DR expression (Lederman et al.,
2011; Bisset et al., 1998; Cobos Jiménez et al., 2016) which is most
pronounced during viremia and in case of poor immunologic recovery.
However, not all studies were able to reproduce these ﬁndings and
conﬂicting data or only subtle eﬀects of HIV infection on monocytes
and plasma cytokines were observed (Hattab et al., 2015; Wada et al.,
2015; Hearps et al., 2012b; Shah et al., 2015; Castley et al., 2014; Kooij
et al., 2016). Several theories have been suggested to cause the
sustained immune activation in HIV infection, which include microbial
translocation, continued viral replication and pyroptosis (Brenchley
et al., 2006; Doitsh et al., 2014). cART-induced reduction of viral load
is likely to diminish the degree of immune activation. Indeed, it has
been shown that early after cART is initiated, markers of immune
activation drop dramatically (Wada et al., 2015; Deeks et al., 2004).
However, the long-term eﬀects of cART treatment have been less well
studied. One study showed that markers of immune activation ﬂuctuate
substantially over the course of chronic treatment (French et al., 2009),
while another study demonstrated that T cell activation markers can
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reach levels comparable to uninfected controls as early as 6 months
after treatment initiation (Chevalier et al., 2013).
The eﬀect of long-term cART on immune activation after initial
viral suppression remains under-investigated. The question whether
immune activation persists in well-suppressed patients with good
immunological recovery is of paramount importance, especially con-
sidering the suspected risks on increased mortality and morbidity. In
the current study, we investigated the eﬀect of long-term cART
treatment on a comprehensive panel of biomarkers of immune activa-
tion in HIV patients. We investigated the temporal eﬀect of cART in
cross-sectional matched groups of well-treated HIV infected indivi-
duals without clinically apparent co-morbidities. We found that after
the ﬁrst year of therapy-induced HIV suppression no additional eﬀect
on inﬂammation markers is observed. Importantly, the residual
immune activation status in this population with well-treated HIV-
infection is comparable to levels observed in healthy individuals.
2. Methods
2.1. Subjects
Fifty individuals infected with HIV were recruited between 2012
and 2013 from the outpatient clinic of the Erasmus MC and partici-
pated in the cross-sectional TREVI cohort, a Dutch study focusing on
neurocognitive disorders in patients living with HIV (Langerak et al.,
2015). A selection of 10 individuals per group was performed based on
the duration of cART treatment. The groups consisted of patients not
receiving treatment, patients during the early phase of treatment (1
year on cART), patients during an intermediate phase of treatment (3
and 5 years on cART) and patients on long-term treatment (10 years of
cART). A group of 10 uninfected otherwise healthy individuals was
used as control (HC). Groups were matched on age, sex and (with the
exception of the control group) smoking. Patient history was assessed
for major co-morbidities, such as active hepatitis B or C and malig-
nancies. Although all HIV patients are at risk of major co-morbidities,
at the time of sampling no clinical signs were apparent yet. Age-related
non-communicable diseases were reduced to a minimum in al groups.
All participants provided written informed consent, and the study was
approved by the ethical committee of the Erasmus MC.
2.2. Assessment of the frequency of leukocyte subpopulations
Blood was collected in heparin BD Vacutainer® CPT™ tubes, and
PBMC were isolated within 24 h and cryopreserved in RPMI-1640
medium and DMSO (20%) for later use. Plasma was collected in 3.2%
citrated Vacutainer® tubes, spun twice and cryopreserved for later use.
Viable PBMC were stained with the following antibodies: CD3-FITC/
PE-Cy-7, CD45RO-PE, HLA-DR-PerCP-Cy5.5, CD8-APC-H7/FITC,
CD4-PE-Cy7/APC-H7, CD38-eFluor450, CD14-PE/eFluor450, CD56-
APC, CD19-APC-eFluor780, and CD16-eFluor450 (Biolegend/
eBioscience/BD Biosciences). Flowcytometry was performed using
the MACSQuant® (Miltenyi Biotec) and analyzed using Flowjo software
(Treestar). The frequencies of lymphocytes and monocytes were
determined on the basis of their forward/sideward scatter (FSC-SSC)
proﬁle.
2.3. Intracellular cytokine staining
Cytokine production by monocytes was determined as described
before (Liu et al., 2011). Brieﬂy, PBMC were seeded at 0.25x106/250 μl
with serum free X-vivo media (Lonza) alone, or in combination with
2 ng/ml LPS Minnesota (TLR4 agonist, Sigma), or 1 μg/ml R848
(TLR7/8 agonist, Enzo Lifesciences). Cells were incubated for 2 h
and treated with 10 μg/ml brefeldin A (Sigma) to block protein
secretion. After 7 h of incubation, cells were ﬁxed with 2% formalde-
hyde and stained for CD14. Cells were then permeabilized with 0.5%
saponin and stained with antibodies against MIP-1β-PE, TNF-PE-Cy7;
MCP-1-APC; Tissue Factor (CD142)-PE, IL-6-FITC, IL-8-FITC. For the
intracellular staining of NK and T cells, 0.5 x106 PBMC were incubated
in a 96 wells plate for 1 h in 200 μl RPMI-1640 medium with 5% FCS
and subsequently ﬁxed with 2% formaldehyde. Cells were then washed
once with PBS, permeabilized with 0.5% saponin and stained with
antibodies against TRAIL-FITC, granzyme B-PE, perforin-PerCp-
Cy5.5, CD56-APC and CD3-eFluor450. 0.5 x106 PBMC were incubated
in a 24 wells plate for 21 h in 250 μl RPMI-1640 medium with 5% FCS
in the presence or absence of IL-12 (0.25 ng/ml, Miltenyi) and IL-18
(50 ng/ml, R &D systems). Cells were ﬁxed, stained for CD3 and CD56,
permeabilized and stained with antibodies against IFNγ-FITC (Spaan
et al., 2016). Flowcytometry and analysis was performed as described
earlier. All antibodies were purchased from Biolegend, eBioscience or
BD Biosciences.
2.4. Assessment of plasma biomarkers using multiplex
immunoassays and ELISA
The ProcartaPlex human multiplex assay was used to detect
cytokines in plasma (Aﬀymetrix eBioscience). Targets included sIL-
2R, interferon-gamma-inducible protein (IP)10, sTNFRII, IL-10, D-
dimer, and CRP. The assays were analysed on the Ap54 microsphere
based multiplex LUMINEX 100 FIDIS v3 using ProcartaPlex Analyst
1.0 Software. Plasma levels of sCD14 were measured sandwich ELISA
using rat anti-human sCD14 (clone 55-3; BD Biosciences), and
biotinylated anti-human sCD14 (clone 3-C39; BD Biosciences).
Visualization of the assay was using streptavidin-horseradish perox-
idase and TMB, and the optical density (OD) at 450 nm was measured
on a Bio-Rad imager.
2.5. Statistical analysis
Statistical analysis was performed using SPSS software (IBM,
v21.0). Cell populations of each sample were measured as percentage
within the parent population and compared between subgroups.
Continuous variables were assessed for normality and signiﬁcance
between groups was detected using a one-way ANOVA. A post-hoc
correction for multiple comparisons was applied using Tukey HSD test
when equal variances were assumed. For analysis of data with clear
heterogeneity of variances, a Games-Howel test was applied.
Table 1
Basic characteristics of HIV-infected cases and uninfected controls.
HC 0 1 3 5 10
Years on
cART
0 (0) 0 (0) 1.1 (0.5) 3.0 (0.3) 5.2 (0.6) 10.8 (2.3)
Age (yr) 44 (4) 45 (4) 42 (8) 44 (2) 45 (8) 45 (5)
Males (%) 100 100 100 100 100 100
Caucasian 90 100 100 100 100 100
CD4 nadir n.a. 511 (209) 296 (151) 257 (131) 200 (77) 200 (99)









0 (0) 4.4 (2.8) 2.3 (1.2) 4.5 (1.8) 6.9 (2.4) 12.3 (2.4)
Smoking
(%)
0 40 50 40 50 50
Each group consists of 10 individuals. n.a = not applicable. HC = healthy controls. 0, 1, 3,
5, 10 = HIV groups with corresponding cART treatment duration (in years). The
standard deviation is presented in brackets.
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3. Results
Table 1 displays the characteristics of the study population. All HIV
patients and HC were male, and almost exclusively Caucasian. The
mean age of patients combined was 45 years and did not signiﬁcantly
diﬀer between the HIV groups and HC (p=0.848). The CD4 nadir count
and viral load were highest at baseline (both p < 0.0001). The CD4
counts were comparable across HIV groups (p=0.978). To minimize
the eﬀect of smoking as a potential confounder, we choose to balance
this risk factor across the HIV groups. All patients were free from
malignancies and active hepatitis co-infection. Only three patients had
been previously diagnosed with comorbidities with a possible eﬀect on
inﬂammation. Two patients had well-controlled diabetes and one
patient had minor myocardial ischemia 5 years before sampling for
which he received adequate treatment. One diabetes patient was on
cART for 3 years; the other diabetes patient and the myocardial
ischemia patient were on cART for 10 years. None of the patients
demonstrated signiﬁcantly stronger inﬂammatory responses compared
to other subjects.
3.1. Proportions of lymphocyte subsets not aﬀected by prolonged HIV
suppression by cART
Phenotypic characterization was performed to assess the impact of
prolonged HIV suppression by cART on the percentage of blood
lymphocyte populations. Fig. 1A shows the proportion of CD4+ and
CD8+ T cells, CD19+ B cells, CD56+CD3- NK cells, and CD56+CD3+
NKT cells within the lymphocyte population. All HIV positive patients
showed signiﬁcantly lower CD4+ and higher CD8+ T cell percentages in
comparison to healthy control subjects and these percentages did not
normalize in patients with prolonged cART. Our patient population
consists of chronically HIV-infected patients in which treatment was
initiated when CD4 counts dropped below 350x106 CD4+ T cells/ml
following previous guidelines (European AIDS Clinical Society
Guidelines, 2014). The proportions of CD19+ B cells, NK cells, and
NKT cells did not diﬀer between untreated patients and those treated
with cART for 1, 3, 5 or 10 years, and were comparable to those
observed for healthy individuals.
3.2. Activation of CD4+ and CD8+ T cells reduced during cART
induced HIV suppression
Next, we investigated the impact of duration of cART on the
activation status of lymphocyte subpopulations. While no diﬀerences
in CD45RO expression was observed in CD4+ and CD8+ T cells before
and during cART (data not shown), the fraction of CD4+ and CD8+ T
cells being HLA-DR+CD38+ were reduced in patients on cART and
seemed to normalize to the low levels observed in healthy controls after
3–5 years (Fig. 1B). Also in patients treated with cART for 1 year only,
this eﬀect was observed, albeit not signiﬁcant (p=0.069).
3.3. Monocytes seem unaﬀected by HIV infection and subsequent
cART initiation
Circulating monocytes can be subdivided on the basis of expression
of CD14 and CD16 into inﬂammatory (CD14++CD16+), patrolling
(CD14+CD16+) and traditional (CD14+CD16-) monocytes. The propor-
tions of inﬂammatory, patrolling and traditional monocytes seem
unchanged by HIV infection, and cART initiation has no signiﬁcant
impact on their relative distribution (Fig. 2A). Also, the proportions of
monocytes producing the pro-inﬂammatory cytokines TNF, IL-6, MIP-
1β and MCP-1 (Fig. 2B) as well as the anti-inﬂammatory cytokine IL-
10 (data not shown) were similar between healthy subjects and HIV
patients, irrespective of treatment duration. Only when all HIV patients
were pooled, signiﬁcantly higher proportions of monocytes producing
MCP-1 (p=0.003), IL-8 (p=0.008; data not shown) and Tissue Factor
(p=0.011; data not shown) were observed as compared to healthy
control subjects. However, it is important to note that the levels of
induction of pro-inﬂammatory cytokines by monocytes of HIV-infected
patients are variable.
3.4. NK cells seem unaﬀected by HIV infection and subsequent cART
initiation
Under pro-inﬂammatory conditions, NK cells are able to mount a
potent antiviral response, primarily mediated by IL-12 and IL-18. This
results in the production of IFNγ, a cytokine crucial in controlling viral
infections (Murphey et al., 2012). NK cells are able to induce killing of
virus-infected host cells by self-recognition and subsequent production
Fig. 1. Distribution of CD4, CD8, CD19, NK and NKT cells within lymphocyte populations. HC had more CD4 cells and less CD8 cells compared to all HIV+ groups. Below: the
proportion of HLA DR positivity of corresponding CD4 and CD8 population. A signiﬁcantly higher percentage of HLA-DR+CD38+ cells in the CD4 population of untreated HIV+ patients
was found compared to patients more than 5 years on treatment and HC. The percentage of HLA-DR+ cells in CD8 population was higher in untreated HIV+ patients compared to
patients longer than 3 years on treatment. 0, 1, 3, 5, 10 = HIV infected patients in ascending order of antiretroviral treatment duration (0, 1, 3, 5 or 10 years of therapy). HC = healthy
controls. * p≤0.05; ** p≤0.01; *** p≤0.001.
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of enzymes, like perforin, granzyme B and membrane expression of
TRAIL. Fig. 3A illustrates the frequency of NK cells expressing TRAIL,
granzyme B and perforin, and demonstrates no signiﬁcant diﬀerences
between expression of these markers in NK cells of patients compared
to HC, albeit that the expression of granzyme B appeared higher in
patients than controls. Also, no clear association with treatment
Fig. 2. (A) Proportion of traditional (CD14+CD16-), inﬂammatory (CD14+CD16+) and patrolling (CD14dimCD16+) monocytes in otherwise healthy uninfected controls (HC) and
patients with HIV infection in ascending order of cART treatment duration (0, 1, 3, 5 or 10 years of therapy). The variation of CD16 expression within groups was considerable but no
statistically signiﬁcant diﬀerences were observed between groups. (B) The frequency of monocytes expressing inﬂammatory markers of otherwise healthy uninfected controls (HC) and
patients with HIV infection in ascending order of cART treatment duration (0, 1, 3, 5 or 10 years of therapy). No signiﬁcant diﬀerence was found across groups in baseline intracellular
levels of TNF, IL-6, MIP-1β and MCP1.
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duration was observed. The range of perforin expressing cells was high,
probably reﬂecting a large intra-individual spread of this marker. To
evaluate the function of NK cells, IFNγ production was induced with
IL-12 and IL-18. The frequencies of IFNγ-producing NK cells were
comparable in all HIV groups, and did not statistically diﬀer from HC.
3.5. Except for IP-10, the levels of inﬂammatory markers in plasma
did not decline during cART suppressed HIV-infection
Finally, plasma levels of various pro-inﬂammatory biomarkers were
determined. As shown in Fig. 4, plasma IP-10 levels were higher in
untreated HIV patients as compared HC. As a consequence of early,
intermediate and long-term cART the plasma IP-10 levels declined to
the levels observed in HC. sTNF-RII and sCD14 levels were also
signiﬁcantly higher in untreated HIV patients compared to HC, but did
not decline on cART. The plasma levels of sIL-2R and CRP showed a
trend towards higher levels in the untreated group as compared to HC,
but again the levels did not signiﬁcantly decline during the course of
cART. Plasma D-dimer levels were not increased and displayed no
change during the course of cART.
4. Discussion
A number of studies have demonstrated that eﬀective cART
treatment of chronic HIV patients result in reduced activation of
components of the patient's immune system. Most studies evaluated
the immune eﬀects during the ﬁrst year after start of therapy. We now
show the immune eﬀects of HIV suppression up to 10 years after start
of cART in a well-deﬁned cross-sectional study cohort. Importantly,
albeit that the selected patients are at risk of major co-morbidities,
including hepatitis and malignancies, at the time of sampling no
clinical signs of co-morbidities were apparent yet. Our ﬁndings show
that after the ﬁrst year of therapy-induced HIV suppression no
additional eﬀects on inﬂammation markers were observed in HIV-
infected patients without major co-morbidities. Our observation of no
or mild immune activation in suppressed HIV-infection questions the
impact of ongoing inﬂammation on co-morbidity and mortality ob-
served in HIV-infected patients without any previous major co-
morbidities.
In line with previous studies, we observed that untreated HIV
infection is associated with an increased expression of the activation
markers HLA-DR and CD38 on CD4+ and CD8+ T cells, indicating
occurrence of the persistent immune activation in untreated HIV-
infected individuals (Paiardini and Müller-Trutwin, 2013; Hunt, 2012;
Wittkop et al., 2013). Importantly, the T cell activation is not
permanent, since the frequencies of HLA-DR+CD38+ T cells drop
during the early stage (1 year) after treatment initiation and plateau
during the intermediate (3 and 5 years) and long-term (10 years) phase
of treatment. We did not detect a signiﬁcant diﬀerence in this marker
when comparing intermediate and long-term treatment to healthy
controls. This is in line with a number of studies, although conﬂicting
data exists. Some studies investigating the level of activated T cells in
well treated HIV infected individuals report levels comparable to
uninfected controls (Lederman et al., 2011; Bisset et al., 1998;
Chevalier et al., 2013), others ﬁnd a modest but signiﬁcant increase
(Cobos Jiménez et al., 2016; Vinikoor et al., 2013). These contradictory
ﬁndings point towards additional confounding factors that inﬂuence
the activation status of T cells in the absence of viremia. Behavioral and
socio-demographic risk factors might play a role, as well as the timing
of treatment initiation (Jain et al., 2013).
Diﬀerent from the eﬀect of chronic HIV infection on T cells, we
were unable to ﬁnd modulation of monocyte and NK cell frequencies,
phenotype or function as a consequence of the ongoing infection, and
as a result the additional eﬀect of cART could not be assessed. Little
information is available in literature on the eﬀect of long-term cART on
NK cells, but a number of studies in monocytes have been performed.
Our results are in line with studies that show that monocytes do not
exhibit an inﬂammatory proﬁle (Castley et al., 2014; Fischer-Smith
Fig. 3. Intracellular markers associated with immune activation in NK cells. Intracellular expression of TRAIL, granzyme B, IFNγ and perforin by NK cells. For the IFNγ assay, prior
stimulation with IL-12 and IL-18 was performed. No unidirectional trend of immune activation level was observed with treatment duration. TRAIL: TNF-related apoptosis-inducing
ligand. IFN: interferon.* p < 0.05; ** p < 0.01; *** p < 0.001.
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et al., 2008; Amirayan-Chevillard et al., 2000; Jaworowski et al., 2006).
In studies where increased CD16+ monocyte subsets are identiﬁed,
these observations are often in the context of viremia (Funderburg
et al., 2012; McCausland et al., 2015; Jaworowski et al., 2006).
We observed a large variation on the production of intracellular
cytokines in monocytes between individuals. These outliers could
represent patients that are at increased risk for illnesses associated
with an activated myeloid phenotype. The presence of patrolling and
inﬂammatory monocytes is strongly associated with cardiovascular
disease in the setting of HIV infection (McKibben et al., 2015).
However, our patients show similar percentages of patrolling and
inﬂammatory monocytes and only a minority of HIV-infected patients
shows elevated production by monocytes of pro-inﬂammatory cyto-
kines. Considering the absence of inﬂammatory proﬁle in other
subjects, we expect this phenomenon not to be HIV-related. It is
tempting to speculate that HIV infection does not increase the risk of
cardiovascular disease in patients in the absence of prior risk factors.
Longitudinal studies are needed to formally address this issue.
In line with the eﬀects of cART on T cell activation, we also
observed that plasma IP-10 levels signiﬁcantly declined during the ﬁrst
year after start of treatment, and normalized during continued treat-
ment as compared to the levels observed in healthy individuals. Our
results corroborate with a previous study where no additional eﬀect of
treatment was observed after one year of treatment (Wada et al., 2015).
However, others showed that the same plasma biomarkers have shown
to correlate with morbidity and mortality (Kuller et al., 2008; Kalayjian
et al., 2010; Sandler et al., 2011). In this context, IL-6 has been studied
most extensively for its predictive value (Kuller et al., 2008; Béténé
et al., 2014; Nordell et al., 2014). However, Borges et al. elegantly
demonstrated using the data from these 3 major clinical trials
representing close to 10,000 patients that plasma IL-6 can be
inﬂuenced by a variety of other, non-HIV related factors like age,
smoking and co-morbidities (Borges et al., 2015). The aim of our study
was to investigate the speciﬁc eﬀect of cART on the level of immune
activation. We therefore matched all patients on age and smoking
status and excluded individuals with potentially confounding co-
morbidities. Importantly, the other biomarkers tested, sIL-2R, sTNF-
RII, D-dimer, CRP, and sCD14, did not demonstrated a signiﬁcant
reduction, albeit that for some elevated levels were observed in HIV
patients, and a trend towards decline was observed on cART.
In conclusion, our ﬁndings suggest that in our cross-sectional
cohort consisting of HIV patients of the same age and devoid of
clinically apparent co-morbidities, the modulation of immune para-
meters as a consequence of persistent HIV infection is relatively weak.
In this, the majority of monocyte and NK cell markers as well as the
serum biomarkers tested, resemble those in healthy individuals. cART
reduced normalization of the T cell activation status and plasma IP-10
levels were observed early following treatment initiation, and no
additional immune eﬀects were observed upon continued treatment
for up to 10 years. The data therefore questions the concept of chronic
inﬂammation in HIV as the driving mechanism in the development of
long-term co-morbidities in HIV as suggested by others (Cobos
Jiménez et al., 2016; Castley et al., 2014; Tenorio et al., 2014), and
leave room for alternative explanations, such as the eﬀects of lifestyle
factors (smoking, obesity, drug abuse), sexual behavior, aging, and
changes in cellular metabolism due to HIV.
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Fig. 4. Plasma biomarkers measured in plasma of HIV infected patients in ascending order of treatment duration and healthy controls. Plasma levels of sIL-2R, IP-10, sTNF-RII, D-
dimer, CRP and sCD14 are presented. Results are in pg/ml. sIL-2R= soluble IL-2 receptor. IP-10= Interferon gamma-induced protein 10. TNFRII= TNF receptor II. CRP= C-reactive
protein. * p < 0.05; ** p < 0.01; *** p < 0.001.
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